Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...
Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second ...
Like many Americans, I’m constantly overwhelmed by stress. It leads to restless nights, unproductive afternoons and overall feelings of dread. When I was introduced to Tersa’s $10,000 Sava immersive ...
Investors in Cassava Sciences Inc (Symbol: SAVA) saw new options become available today, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to ...
Cassava Sciences (NASDAQ:SAVA) is extending ongoing open-label extension trials of its lead drug candidate, simufilam, in Alzheimer’s disease by up to an additional 36 months. “Cassava Sciences will ...
The Alzheimer’s drug market climbed to a value of $6.34 billion in 2020, according to research company IMARC, and there are various pharmaceutical firms with Alzheimer’s drugs in their pipelines. One ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results